A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Schizophrenia

In brief

Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

Key facts

Study ID
NCT06894212
Run by
Otsuka Pharmaceutical Development & Commercialization, Inc.
People needed
522
Starts
2025-02-28
Expected to finish
2026-10-29
Last updated by the study team
2026-07-31

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.